Eun Su Park

Eun Su Park

Auto-generated profile, based on publicly available information

Eun Su Park

Vivian L. Smith Department of Neurosurgery, McGovern Medical School (O.M., B.H.F., J.J., H.P., S.M.W., J.E.P., E.S.P., P.R.C., E.K.), The University of Texas Health Science Center at Houston

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EPEun S. Park
Eun S. Park
SKSehee Kim
Sehee Kim
SHShuning Huang
Shuning Huang
JYJi Young Yoo
Ji Young Yoo
JKJakob Körbelin
Jakob Körbelin
EKEunhee Kim
Eunhee Kim

1 January 2015 in Neurobiology of Aging
Verified
Journal Article
Open access
KLKang-Woo Lee
Kang-Woo Lee
JWJong-Min Woo
Jong-Min Woo
JIJoo-Young Im
Joo-Young Im
EPEun S. Park
Eun S. Park
LHLiqiang He
Liqiang He
MMM. Maral Mouradian
M. Maral Mouradian
α-Synuclein is a key pathogenic protein in α-synucleinopathies including Parkinson's disease, and its overexpression and aggregation in model systems are associated with a neuroinflammatory response and increased oxidative stress. Apoptosis signal-regulating kinase 1 (ASK1) is activated upon stress signaling events such as oxidative stress and is a central player linking oxidative stress with neuroinflammation. Here, we demonstrate that overexpression of human α-synuclein activates ASK1 in both PC12 cells and in the brains of α-synuclein transgenic mice. Deleting ASK1 in mice mitigates the neuronal damage and neuroinflammation induced by α-synuclein and improves performance of the animals on the rotarod. ASK1 deletion does not impact the aggregation profile or phosphorylation state of α-synuclein in the mouse brain. These results collectively implicate ASK1 in the cascade of events triggered by α-synuclein overexpression, likely because of the inflammatory response and oxidative stress that lead to ASK1 activation. These conclusions raise the possibility that potent antioxidants and anti-inflammatory agents may ameliorate the phenotype of α-synucleinopathies.

16 February 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
JPJung-Eun Park
Jung-Eun Park
BFBridger Hayes Freeman
Bridger Hayes Freeman
HPHyejin Park
Hyejin Park
SKSehee Kim
Sehee Kim
ABAdrian E Bafor
Adrian E Bafor
EPEun S Park
Eun S Park
Somatic KRAS (KRAS G12V ) mutation in endothelial cells (EC) induces brain arteriovenous malformation (bAVM) that could lead to vascular instability and ultimately bleeding. However, the causes of bAVM instability remain unclear. Here we demonstrate that KRAS G12V expressing cultured ECs (KRAS-G12V-EC) have increased expression of pro-inflammatory mediators and reduced expression of blood-brain-barrier (BBB) junction constituents. The conditioned medium from KRAS-G12V-EC can activate BV2-microglia (BV2-MG) and conditioned media from this primed BV2-MG can compromise the expression of EC-junction constituents when added to wild-type ECs. In an in vitro BBB model, KRAS-G12V-EC form a dysfunctional EC barrier that is further disrupted, leading to lower transendothelial electrical resistance and increased FITC-dextran leakage when blood-derived macrophages (Mφ) are included. KRAS-G12V-EC potently stimulates BV2-MG chemotaxis. In vitro BBB leakage and BV2-MG chemotaxis were inhibited by treatment with the anti-inflammatory drug minocycline in the KRAS-G12V-EC. In our bAVM mouse model that uses AAV-BR1-KRAS G12V injection to produce EC expression of KRAS G12V in the brain, minocycline injection reduced production of inflammatory cytokines by bAVM nidus, reduced leakage of BSA-647, and restored VE-cadherin expression on malformed vessels. Our findings suggest that KRAS-G12V-EC can activate local MG/Mφ that causes vascular inflammation and instability of malformed vessels in bAVM.

9 November 2009 in Analytical Chemistry
Verified
Journal Article
Closed access
EPEun Su Park
Eun Su Park
JSJohn Sieber
John Sieber
CGCharles Guttman
Charles Guttman
KRKirk Rice
Kirk Rice
KFKathleen Flynn
Kathleen Flynn
GHGale Holmes
Gale Holmes

1 March 2026 in Stroke
Verified
Journal Article
Closed access
OMOhnmar Myint
Ohnmar Myint
BFBridger Hayes Freeman
Bridger Hayes Freeman
JJJaeyeong Jeong
Jaeyeong Jeong
HPHyejin Park
Hyejin Park
SWSamantha M. Wilfur
Samantha M. Wilfur
EKEunhee Kim
Eunhee Kim
BACKGROUND: Brain arteriovenous malformations (bAVMs) are a major risk factor for intracerebral hemorrhages in young patients. Recent clinical studies have reported that the majority of human bAVMs harbor somatic KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations. In our previous study, we confirmed the causal role of endothelial KRAS G12V mutation in bAVM development in mice through hyperactivation of the MEK/ERK (mitogen-activated protein kinase kinase/extracellular signal–regulated kinase) pathway. However, the treatment efficacy of targeting MEK/ERK signaling in bAVMs, regarding clinical and biological outcomes, remains unclear. METHODS: In this study, we used the US Food and Drug Administration–approved MEK inhibitor, trametinib, to treat mice with bAVMs induced by brain endothelial cell (EC)–specific KRAS G12V overexpression (KRAS G12V/bEC mice). We treated KRAS G12V/bEC mice with either vehicle or trametinib and evaluated outcomes on mortality and the alteration of bAVMs, and the hemorrhages. We also determined the effect of trametinib on the endothelial-to-mesenchymal transition, which has recently been explored in human bAVMs and implicated in bAVM pathology, in bAVMs of KRAS G12V/bEC mice and cultured mouse ECs transfected with KRAS G12V (EC G12V ). RESULTS: We observed that trametinib significantly improved survivability, potentially through improved vessel integrity and reduction in the severity of bAVM ruptures. Our longitudinal observation of mice bAVMs using noninvasive magnetic resonance imaging revealed that trametinib decreased the total hemorrhagic volume at 8 weeks of treatment when administered at 1 mg/kg compared with the vehicle group, which was confirmed by histological analyses. In addition, trametinib altered endothelial-to-mesenchymal transition by reducing the expression levels of mesenchymal markers (N-Cad [N-cadherin], Slug, CD44 [cluster of differentiation 44]) and increasing an EC marker (VE-Cad [vascular endothelial cadherin]) in bAVMs of KRAS G12V/bEC mice. Trametinib also decreased proliferation (Ki-67) and angiogenic (CD34 and pVEGFR2 [phosphor-vascular endothelial growth factor receptor 2]) markers in KRAS G12V/bEC mice’s bAVMs. We also confirmed that trametinib normalized the endothelial-to-mesenchymal transition-associated marker expression and functions in EC G12V . CONCLUSIONS: Our data demonstrate that trametinib improves bAVM pathology by reducing hemorrhagic risk and normalizing endothelial-to-mesenchymal transition. These findings suggest that trametinib is a promising agent to treat patients with bAVM.

18 November 2026 in bioRxiv
Verified
Preprint
Open access
EPEun S. Park
Eun S. Park
JPJungEun Park
JungEun Park
HPHyejin Park
Hyejin Park
OMOhnmar Myint
Ohnmar Myint
SKSung Wook Kang
Sung Wook Kang
EKEunhee Kim
Eunhee Kim
BACKGROUND: Hemorrhagic conversion is the most devastating complication of brain arteriovenous malformations (bAVMs). However, endothelial mechanisms promoting macrophages (Mφ) recruitment, microglia (MG) activation, and bAVM lesion instability remain unclear. We investigated vascular cell adhesion molecule-1 (VCAM1) as a mediator linking oncogenic endothelial signaling to myeloid cell responses and hemorrhagic progression in bAVMs. METHODS: We performed integrated transcriptomic analysis of human bAVM and epilepsy-control brain tissues, with validation in local bAVM specimens. Transcriptomic and proteomic analyses of bAVM lesions and intact brain tissues from mutant KRAS-induced bAVM mice were followed by histological validation. Using AAV-BR1-KRASG12V-injected Cx3cr1-gfp;Ccr2-rfp mice, we performed intravital imaging to assess Mφ/MG responses to VCAM1 neutralization. Hemorrhage and myeloid cell responses were also evaluated following endothelial-specific VCAM1 deletion. Plasma soluble VCAM1 (sVCAM1) was measured in patients with unruptured and ruptured bAVMs and unruptured aneurysm controls. Effects of sVCAM1 on MG activation were examined in vitro. RESULTS: Integrated human endothelial bulk and single-cell RNA-sequencing and tissue validation identified VCAM1 upregulation in bAVMs, including unruptured lesions. Plasma analyses showed increased sVCAM1 in unruptured and ruptured bAVM patients compared with unruptured aneurysm controls. In mutant KRAS-induced bAVM mice, transcriptomic and proteomic analyses demonstrated increased VCAM1 expression, with endothelial localization confirmed histologically. In vitro, mutant KRAS increased sVCAM1 production, while recombinant sVCAM1 stimulated inflammatory mediator expression in MG. Both MG and Mφ expressed VLA-4, a major VCAM1 receptor. Intravital imaging showed that VCAM1 neutralization reduced Mφ accumulation and MG activation, while early VCAM1 neutralization reduced hemorrhagic burden. Consistently, endothelial-specific VCAM1 deletion reduced Mφ accumulation, MG activation, and hemorrhage volume in bAVM mice and improved behavioral performance. CONCLUSIONS: These findings identify endothelial VCAM1 as an upstream mediator linking mutant KRAS signaling to myeloid cell responses and hemorrhagic progression in bAVMs. This study establishes endothelial VCAM1 as a potential therapeutic target for attenuating hemorrhagic progression.